Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites

Authors: Nynke GL Jager, Rutger HT Koornstra, Andrew D Vincent, Ron HN van Schaik, Alwin DR Huitema, Tiny M Korse, Jan HM Schellens, Sabine C Linn, Jos H Beijnen

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Tamoxifen has dramatically reduced the recurrence and mortality rate of estrogen receptor positive breast cancer. However, the efficacy of tamoxifen varies between individuals and 40% of patients will have a recurrence despite adjuvant tamoxifen treatment. Factors that predict tamoxifen efficacy would be helpful for optimizing treatment. Serum concentrations of the active metabolite, endoxifen, may be positively related to treatment outcome. In addition, hot flashes are suggested to be positively associated with tamoxifen treatment outcome.

Methods

We investigated in a series of 109 patients whether the frequency and severity of hot flashes were related to concentrations of tamoxifen and its metabolites. A serum sample of all patients was analyzed for the concentration of tamoxifen, N-desmethyltamoxifen, endoxifen and 4-hydroxytamoxifen, as well as for estradiol concentrations and several single nucleotide polymorphisms in CYP2D6. Additionally, these patients completed a questionnaire concerning biometric data and treatment side effects.

Results

We found no evidence supporting an association between concentrations of tamoxifen or metabolites and either the frequency or severity of hot flashes in the covariate unadjusted analyses. However, including interactions with menopausal status and pre-treatment hot flash (PTHF) history indicated that post-menopausal women with PTHF experienced an increasing frequency of hot flashes with increasing serum concentrations of tamoxifen and its metabolites. This finding was not altered when adjusting for potential confounding factors (duration of tamoxifen treatment, CYP2D6 phenotype, estradiol serum concentration, age and body mass index). In addition we observed a positive association between body mass index and both hot flash frequency (p = 0.04) and severity (p < 0.0001). We also observed that patients with lower estradiol levels reported more severe hot flashes (p = 0.02).

Conclusions

No univariate associations were observed between concentrations of active tamoxifen metabolites and either the frequency or severity of hot flashes during treatment. However, the frequency of hot flashes may be exacerbated by higher serum concentrations of tamoxifen and its metabolites in post-menopausal women with a history of hot flashes prior to tamoxifen treatment.
Appendix
Available only for authorised users
Literature
1.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005, 365 (9472): 1687-1717.CrossRef
2.
Ring A, Dowsett M: Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004, 11 (4): 643-658. 10.1677/erc.1.00776.CrossRefPubMed
3.
Beelen K, Zwart W, Linn SC: Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?. Nat Rev Clin Oncol. 2012, 9 (9): 529-541. 10.1038/nrclinonc.2012.121.CrossRefPubMed
4.
Lim YC, Desta Z, Flockhart DA, Skaar TC: Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005, 55 (5): 471-478. 10.1007/s00280-004-0926-7.CrossRefPubMed
5.
Johnson MD, Zuo H, Lee K-H, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA, Skaar TC: Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004, 85 (2): 151-159. 10.1023/B:BREA.0000025406.31193.e8.CrossRefPubMed
6.
Lu WJ, Desta Z, Flockhart DA: Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res Treat. 2012, 131 (2): 473-481. 10.1007/s10549-011-1428-z.CrossRefPubMed
7.
Teunissen SF, Rosing H, Seoane MD, Brunsveld L, Schellens JHM, Schinkel AH, Beijnen JH: Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques. J Pharm Biomed Anal. 2011, 55 (3): 518-526. 10.1016/j.jpba.2011.02.009.CrossRefPubMed
8.
Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, et al: Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011, 89 (5): 718-725. 10.1038/clpt.2011.32.CrossRefPubMedPubMedCentral
9.
Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, Raptis G, Desnick RJ: Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score. Clin Pharmacol Ther. 2011, 90 (4): 605-611. 10.1038/clpt.2011.153.CrossRefPubMed
10.
Irvin WJ, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, et al: Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol. 2011, 29 (24): 3232-3239. 10.1200/JCO.2010.31.4427.CrossRefPubMedPubMedCentral
11.
Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee K-H, Skaar T, Storniolo AM, Li L, Araba A, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005, 97 (1): 30-39. 10.1093/jnci/dji005.CrossRefPubMed
12.
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, et al: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012, 104 (6): 452-460. 10.1093/jnci/djs126.CrossRefPubMedPubMedCentral
13.
Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thürlimann B, Lyng MB, et al: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial. J Natl Cancer Inst. 2012, 104 (6): 441-451. 10.1093/jnci/djs125.CrossRefPubMedPubMedCentral
14.
Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M: Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol. 2012, 31 (2): 176-180.CrossRefPubMedPubMedCentral
15.
Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT, Karthaus M, Riess H, Lipp HP, Hauschild A, et al: Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011, 22 (3): 524-535. 10.1093/annonc/mdq387.CrossRefPubMed
16.
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996, 88 (21): 1529-1542. 10.1093/jnci/88.21.1529.CrossRefPubMed
17.
Loprinzi CL, Zahasky KM, Sloan JA, Novotny PJ, Quella SK: Tamoxifen-induced hot flashes. Clin Breast Cancer. 2000, 1 (1): 52-56. 10.3816/CBC.2000.n.004.CrossRefPubMed
18.
Love RR, Feyzi JM: Reduction in vasomotor symptoms from tamoxifen over time. J Natl Cancer Inst. 1993, 85 (8): 673-674.CrossRefPubMed
19.
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, WHEL Study Group: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008, 108 (3): 421-426. 10.1007/s10549-007-9612-x.CrossRefPubMed
20.
Cuzick J, Sestak I, Cella D, Fallowfield L, ATAC Trialists’ Group: Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008, 9 (12): 1143-1148. 10.1016/S1470-2045(08)70259-6.CrossRefPubMed
21.
Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Töns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JHM: Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2011, 29 (29): 3862-3868. 10.1200/JCO.2010.33.1298.CrossRefPubMed
22.
Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H: Methodologic lessons learned from hot flash studies. J Clin Oncol. 2001, 19 (23): 4280-4290.PubMed
23.
24.
Teunissen SF, Jager NGL, Rosing H, Schinkel AH, Schellens JHM, Beijnen JH: Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011, 879 (19): 1677-1685. 10.1016/j.jchromb.2011.04.011.CrossRefPubMed
25.
European_Medicines_Agency: Guideline on bioanalytical method validation. 2011, London(UK): EMEA
26.
Food_and_Drug_Administration: Bioanalytical Method Validation. 2001, Rockville, MD (USA): FDA
27.
Lammers LA, Mathijssen RHJ, van Gelder T, Bijl MJ, de Graan A-JM, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RHN: The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer. 2010, 103 (6): 765-771. 10.1038/sj.bjc.6605800.CrossRefPubMedPubMedCentral
28.
Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K, Ziv E: Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012, 132 (3): 1107-1118. 10.1007/s10549-011-1893-4.CrossRefPubMed
29.
Sestak I, Kealy R, Edwards R, Forbes J, Cuzick J: Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol. 2006, 24 (24): 3991-3996. 10.1200/JCO.2005.04.3745.CrossRefPubMed
30.
Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, et al: Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005, 23 (36): 9312-9318. 10.1200/JCO.2005.03.3266.CrossRefPubMed
31.
Erlik Y, Meldrum DR, Judd HL: Estrogen levels in postmenopausal women with hot flashes. Obstet Gynecol. 1982, 59 (4): 403-407.PubMed
32.
Guthrie JR, Dennerstein L, Hopper JL, Burger HG: Hot flushes, menstrual status, and hormone levels in a population-based sample of midlife women. Obstet Gynecol. 1996, 88 (3): 437-442. 10.1016/0029-7844(96)00196-2.CrossRefPubMed
33.
Kronenberg F: Menopausal hot flashes: a review of physiology and biosociocultural perspective on methods of assessment. J Nutr. 2010, 140 (7): 1380S-1385S. 10.3945/jn.109.120840.CrossRefPubMed
34.
Visvanathan K, Gallicchio L, Schilling C, Babus JK, Lewis LM, Miller SR, Zacur H, Flaws JA: Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women. Obstet Gynecol. 2005, 106 (6): 1372-1381. 10.1097/01.AOG.0000187308.67021.98.CrossRefPubMed
35.
Moilanen J, Aalto AM, Hemminki E, Aro AR, Raitanen J, Luoto R: Prevalence of menopause symptoms and their association with lifestyle among Finnish middle-aged women. Maturitas. 2010, 67 (4): 368-374. 10.1016/j.maturitas.2010.08.007.CrossRefPubMed
36.
Freeman EW, Sammel MD, Lin H, Liu Z, Gracia CR: Duration of menopausal hot flushes and associated risk factors. Obstetrics & Gynecology. 2011, 117 (5): 1095-1104. 10.1097/AOG.0b013e318214f0de.CrossRef
37.
Thurston RC, Santoro N, Matthews KA: Adiposity and hot flashes in midlife women: a modifying role of age. J Clin Endocrinol Metab. 2011, 96 (10): E1588-E1595. 10.1210/jc.2011-1082.CrossRefPubMedPubMedCentral
38.
Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S: Symptom prevalence during menopause and factors associated with symptoms and menopausal age. Results from the Norwegian Hordaland Women’s Cohort study. Maturitas. 2011, 70 (4): 383-390. 10.1016/j.maturitas.2011.09.011.CrossRefPubMed
Metadata
Title
Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
Authors
Nynke GL Jager
Rutger HT Koornstra
Andrew D Vincent
Ron HN van Schaik
Alwin DR Huitema
Tiny M Korse
Jan HM Schellens
Sabine C Linn
Jos H Beijnen
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-612

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Multicentric and multifocal versusunifocal breast cancer: differences in the expression of E-cadherin suggest differences in tumor biology

Research article

Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses

Research article

EGF receptor and COX-1/COX-2 enzyme proteins as related to corresponding mRNAs in human per-operative biopsies of colorectal cancer

Research article

Predictors for replanning in loco-regionally advanced nasopharyngeal carcinoma patients undergoing intensity-modulated radiation therapy: a prospective observational study

Reviewer acknowledgement

Reviewer Acknowledgements

Research article

MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits